Top

Published in:

01-05-2014 | Epidemiology

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

Authors: Daniel L. Hertz, Siddharth Roy, John Jack, Alison A. Motsinger-Reif, Amy Drobish, L. Scott Clark, Lisa A. Carey, E. Claire Dees, Howard L. McLeod

Published in: Breast Cancer Research and Treatment | Issue 1/2014

Abstract

The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by drug exposure and patient genetics. The purpose of this analysis was to expand on a previous reported association of CYP2C8*3 and PIPN risk by investigating additional polymorphisms in CYP2C8 and in hundreds of other genes potentially relevant to paclitaxel pharmacokinetics. Clinical data was collected prospectively in an observational registry of newly diagnosed breast cancer patients. Patients treated with paclitaxel-containing regimens were genotyped using the Affymetrix DMET™ Plus chip. Patients who carried the CYP2C8*2, *3, or *4 variant were collapsed into a low-metabolizer CYP2C8 phenotype for association with PIPN. Separately, all SNPs that surpassed quality control were assessed individually and as a composite of genetic ancestry for associations with PIPN. 412 paclitaxel-treated patients and 564 genetic markers were included in the analysis. The risk of PIPN was significantly greater in the CYP2C8 low-metabolizer group (HR = 1.722, p = 0.018); however, the influences of the *2 and *4 SNPs were not independently significant (*2: p = 0.847, *4: p = 0.408). One intronic SNP in ABCG1 (rs492338) surpassed the exploratory significance threshold for an association with PIPN in the Caucasian cohort (p = 0.0008) but not in the non-Caucasian replication group (p = 0.54). Substantial genetic variability was observed within self-reported racial groups but this genetic variability was not associated with risk of grade 2+ PIPN. The pharmacogenetic heterogeneity within a cohort of breast cancer patients is dramatic, though we did not find evidence that this heterogeneity directly influences the risk of PIPN beyond the contribution of CYP2C8*3.

Available only for authorised users

Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L et al (2004) Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22(24):4958–4965PubMedCrossRef

Martin M, Rodriguez-Lescure Ã, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M et al (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100(11):805–814PubMedCrossRef

Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983PubMedCrossRef

Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology. 47(1):115–118PubMedCrossRef

Mielke S, Mross K, Gerds TA, Schmidt A, Wasch R, Berger DP et al (2003) Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 14(10):785–792PubMedCrossRef

van Gerven JMA, Moll JWB, van den Bent MJ, Bontenbal M, van der Burg MEL, Verweij J et al (1994) Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30(8):1074–1077CrossRef

Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D et al (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843–4850PubMedCrossRef

de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B et al (2013) CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 19(12):3316–3324PubMedCrossRef

Hertz DL (2013) Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics 14(9):1065–1084PubMedCrossRef

10.

Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6{alpha}-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54(21):5543–5546PubMed

11.

Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K et al (2012) Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br J Clin Pharmacol 74(1):197–200PubMedPubMedCentralCrossRef

12.

Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7):597–607PubMedCrossRef

13.

Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F et al (2011) Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 11(2):113–120PubMedCrossRef

14.

Leskela S, Jara C, Leandro-Garcia L, Martinez A, Garcia-Donas J, Hernando S et al (2011) Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11(2):121–129PubMedCrossRef

15.

Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA et al (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134(1):401–410PubMedPubMedCentralCrossRef

16.

Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL et al (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24(6):1472–1478PubMedCrossRef

17.

Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V et al (2012) Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 30(25):3051–3057PubMedPubMedCentralCrossRef

18.

Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG et al (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):234–240CrossRef

19.

Sissung TM, English BC, Venzon D, Figg WD, Deeken JF (2010) Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1):89–103PubMedCrossRef

20.

Common terminology criteria for adverse events (CTCAE) version 4.0 (2010) US Department of Health and Human Services, National Institutes of Health, National Cancer Institute

21.

The international HapMap project (2003) Nature 426(6968):789–796CrossRef

22.

He YJ, Shapero MH, McLeod HL (2012) Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. Pharmacogenet Genomics 22(4):322–324PubMedPubMedCentralCrossRef

23.

Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE (2008) Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 23(3):165–174PubMedCrossRef

24.

Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K et al (2010) A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 10(3):191–199PubMedCrossRef

25.

Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8):904–909PubMedCrossRef

26.

Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155(2):945–959PubMedPubMedCentral

27.

Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S et al (2012) Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with gemtuzumab-ozogamicin and fludarabine, cytarabine and idarubicin. Pharmacogenomics J. doi:10.1038/tpj.2012.13 PubMed

28.

Uchiyama T, Kanno H, Ishitani K, Fujii H, Ohta H, Matsui H et al (2012) An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel. Cancer Chemother Pharmacol 69(6):1617–1624PubMedCrossRef

29.

Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Saveria Rotundo M, Ciliberto D et al (2011) Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study. Cancer Biol Ther 12(9):780–787PubMedCrossRef

30.

Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111(8):4106–4112PubMedPubMedCentralCrossRef

31.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19):2553–2560PubMedCrossRef

32.

Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P et al (2012) Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 22(1):1–8PubMedPubMedCentralCrossRef

33.

de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ et al (2013) A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res 19(18):5210–5217PubMedCrossRef

34.

Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G et al (2000) ABCG1 (ABC8), the human homolog of the drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 97(2):817–822PubMedPubMedCentralCrossRef

35.

Tarr PT, Edwards PA (2008) ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J Lipid Res 49(1):169–182PubMedCrossRef

36.

Rainey WE, Kramer RE, Mason JI, Shay JW (1985) The effects of taxol, a microtubule-stabilizing drug, on steroidogenic cells. J Cell Physiol 123(1):17–24PubMedCrossRef

37.

Schaeffer V, Meyer L, Patte-Mensah C, Mensah-Nyagan A (2010) Progress in dorsal root ganglion neurosteroidogenic activity: basic evidence and pathophysiological correlation. Prog Neurobiol 92(1):33–41PubMedCrossRef

38.

Koenig HL, Schumacher M, Ferzaz B, Thi AN, Ressouches A, Guennoun R et al (1995) Progesterone synthesis and myelin formation by Schwann cells. Science 268(5216):1500–1503PubMedCrossRef

39.

Yang IH, Siddique R, Hosmane S, Thakor N, Hoke A (2009) Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration. Exp Neurol 218(1):124–128PubMedCrossRef

40.

Sahenk Z, Barohn R, New P, Mendell JR (1994) Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51(7):726–729PubMedCrossRef

41.

Roglio I, Bianchi R, Camozzi F, Carozzi V, Cervellini I, Crippa D et al (2009) Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst 14(1):36–44PubMedCrossRef

42.

Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A et al (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42(17):2893–2896PubMedPubMedCentralCrossRef

43.

Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C et al (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18(18):5099–5109PubMedPubMedCentralCrossRef

44.

Sucheston L, Zhao H, Yao S, Zirpoli G, Liu S, Barlow W et al (2011) Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130(3):993–1002PubMedPubMedCentralCrossRef

45.

Leandro-Garcia LJ, Leskela S, Jara Sanchez C, Green H, Avall Lundqvist E, Wheeler HE et al (2012) Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 18(16):4441–4448PubMedPubMedCentralCrossRef

46.

Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 20(4 Suppl 3):1–15PubMed

47.

Anziska Y, Helzner EP, Crystal H, Glesby MJ, Plankey M, Weber K et al (2012) The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. J Neurol Sci 315(1–2):129–132PubMedPubMedCentralCrossRef

48.

Soderstrom LH, Johnson SP, Diaz VA, Mainous AG (2012) Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001 to 2004 NHANES. Diabetic Med 29(1):50–55PubMedPubMedCentralCrossRef

49.

Roederer MW, Sanchez-Giron F, Kalideen K, Kudzi W, McLeod HL, Zhang W et al (2011) Pharmacogenetics and rational drug use around the world. Pharmacogenomics 12(6):897–905PubMedCrossRef

Title: Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy
Authors: Daniel L. Hertz
Siddharth Roy
John Jack
Alison A. Motsinger-Reif
Amy Drobish
L. Scott Clark
Lisa A. Carey
E. Claire Dees
Howard L. McLeod
Publication date: 01-05-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-2910-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients

Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine

Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3

Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case–control studies

Premenopausal dietary fat in relation to pre- and post-menopausal breast cancer

Long-term risk of medical conditions associated with breast cancer treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer